BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7704245)

  • 1. p53 immunostaining distinguishes malignant from benign lesions of the gall-bladder.
    Oohashi Y; Watanabe H; Ajioka Y; Hatakeyama K
    Pathol Int; 1995 Jan; 45(1):58-65. PubMed ID: 7704245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical importance of p53 protein in gall bladder carcinoma and its precursor lesions.
    Wee A; Teh M; Raju GC
    J Clin Pathol; 1994 May; 47(5):453-6. PubMed ID: 8027399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 and Ki-67 immunoreactivity and nuclear morphometry of 'carcinoma-in-adenoma' and adenoma of the gall-bladder.
    Takei K; Watanabe H; Itoi T; Saito T
    Pathol Int; 1996 Nov; 46(11):908-17. PubMed ID: 8970203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 and Ki-67 immunoreactivity and nuclear morphometry of 'carcinoma-in-adenoma' and adenoma of the gall-bladder.
    Takei K; Watanabe H; Itoi T; Saito T
    Pathol Int; 1996 Jun; 46(6):426-35. PubMed ID: 8869994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder.
    Kamel D; Pääkkö P; Nuorva K; Vähäkangas K; Soini Y
    J Pathol; 1993 May; 170(1):67-72. PubMed ID: 8100854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of Ki-67 and p53 antigen expression in carcinomas of bile duct and gallbladder.
    Shrestha ML; Miyake H; Kikutsuji T; Tashiro S
    J Med Invest; 1998 Aug; 45(1-4):95-102. PubMed ID: 9864969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater.
    Lee CS; Pirdas A
    Pathology; 1995 Apr; 27(2):117-20. PubMed ID: 7567135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix.
    Cina SJ; Richardson MS; Austin RM; Kurman RJ
    Mod Pathol; 1997 Mar; 10(3):176-80. PubMed ID: 9071723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of p53 in gallbladder carcinoma and in dysplastic and metaplastic lesions of the surrounding mucosa].
    Billo P; Marchegiani C; Capella C; Sessa F
    Pathologica; 2000 Aug; 92(4):249-56. PubMed ID: 11029885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of morphology with assessment of expression of proliferation marker Ki67 antigen and P53 protein in lesions of gall bladder.
    Ramesh O; Gupta M; Kaushik S; Acharya S; Thakur B; Bhardwaj A
    Indian J Pathol Microbiol; 2024 Apr; 67(2):367-373. PubMed ID: 38391184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
    Kleer CG; Giordano TJ; Braun T; Oberman HA
    Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical demonstration of p53 protein in colorectal adenomas and adenocarcinomas. Reliable application of the heat-induced antigen retrieval method to formalin-fixed, paraffin-embedded material.
    Hamana T; Kawai K; Serizawa A; Tsutsumi Y; Watanabe K
    Pathol Int; 1994; 44(10-11):765-70. PubMed ID: 7834078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential diagnosis of atypical epithelium of biopsied gastric mucosa using immunostaining of Ki-67, p53, hMLH1 and MDM2 expression.
    Ito E; Saito K; Takizawa T; Koike M
    J Exp Clin Cancer Res; 2002 Dec; 21(4):527-37. PubMed ID: 12636099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of p53 protein expression with gene mutation in gall-bladder carcinomas.
    Itoi T; Watanabe H; Yoshida M; Ajioka Y; Nishikura K; Saito T
    Pathol Int; 1997 Aug; 47(8):525-30. PubMed ID: 9293532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms. Correlation with histopathology.
    Harlozińska A; Bar JK; Sedlaczek P; Gerber J
    Am J Clin Pathol; 1996 Mar; 105(3):334-40. PubMed ID: 8602615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ki-67 fraction, p53 alteration and numerical chromosome aberrations (chromosomes 7 and 17) in formalin fixed bladder tumors].
    Moch H; Sauter G; Gudat F; Waldman F; Mihatsch MJ
    Verh Dtsch Ges Pathol; 1993; 77():226-30. PubMed ID: 7511286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implication of the p53 protein and Ki-67 antigen immunohistochemistry in malignant fibrous histiocytoma.
    Yang P; Hirose T; Hasegawa T; Seki K; Sano T; Hizawa K
    Cancer; 1995 Aug; 76(4):618-25. PubMed ID: 8625155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and Ki-67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract.
    Lee CS
    Cancer; 1996 Nov; 78(9):1881-7. PubMed ID: 8909306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 and Ki-67 antigen expression in small oral biopsy specimens of salivary gland tumors.
    Lazzaro B; Cleveland D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 May; 89(5):613-7. PubMed ID: 10807720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.